🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Precision Supplemental Imaging in Women With Dense Breasts

RecruitingNAAges 25 Years - 55 YearsFemaleWashington University School of Medicine
NCT07277738 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Recent research has shown that, among women with extremely dense breasts and normal results on mammogram, magnetic resonance imaging (MRI) use has significantly reduced the occurrence of breast cancer that is diagnosed during the time between two regular screening mammograms (also known as interval cancers). The investigators have developed and validated an approach to use the whole mammogram image, develop a mammogram risk score (MRS), and calibrate this to the SEER breast cancer incidence rates for US women. This model (Prognosia Breast) generates an absolute 5-year risk of breast cancer and classifies approximately 5.7% of the population as high risk using the ASCO 3% cut point as used for endocrine therapy to reduce risk. Follow-up generates an incidence of 25.2 cases per 1,000 women per year.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Normal screening mammogram within 90 days prior to enrollment. Bi-Rads of 1 or 2. * Dense breasts, either: * Class C density ("the breasts are heterogeneously dense, which may obscure small masses") * Class D density ("the breasts are extremely dense, which lowers the sensitivity of mammography") * Assigned female at birth. * Between 40 to 74 years of age (inclusive). * Ability to understand and willingness to sign an IRB approved written informed consent document. Exclusion Criteria: * Screening mammogram with BI-Rads of 0. * Contraindication to MRI with contrast (e.g. claustrophobia, metal objects in the body, known sensitivity/allergy to gadolinium). * Prior or concurrent malignancy whose natural history has the potential to interfere with the study intervention (breast cancer or non-classic LCIS). Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial. * Prior MRI screening of the breast. * Known to be BRCA 1/2 positive or presence of any other known high penetrance genetic marker. * Is receiving any endocrine therapy. * Has breast implants. * Is breastfeeding.
💊

What it tests

  • Prognosia Breast
  • Mammogram
  • MRI
📍

Where

1 site
Washington University School of Medicine
St Louis, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy